Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SNDX

SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

20.06USD+0.79 (+4.10%)Market Closed

Market Summary

SNDX
USD20.06+0.79
Market Closed
4.10%

SNDX Alerts

  • 1 major insider buys recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

SNDX Stock Price

View Fullscreen

SNDX RSI Chart

SNDX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-7.08

Price/Sales (Trailing)

13.61

Price/Free Cashflow

-8.32

SNDX Price/Sales (Trailing)

SNDX Profitability

Return on Equity

-48.92%

Return on Assets

-44.31%

Free Cashflow Yield

-12.02%

SNDX Fundamentals

SNDX Revenue

Revenue (TTM)

139.7M

SNDX Earnings

Earnings (TTM)

-240.6M

Earnings Growth (Yr)

-76.04%

Earnings Growth (Qtr)

0.1%

Breaking Down SNDX Revenue

Last 7 days

-0.2%

Last 30 days

-3.4%

Last 90 days

-11.2%

Trailing 12 Months

-5.9%

How does SNDX drawdown profile look like?

SNDX Financial Health

Current Ratio

8.93

SNDX Investor Care

Shares Dilution (1Y)

23.49%

Diluted EPS (TTM)

-3.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20211.5M1.5M13.5M139.7M
20201.5M1.5M1.5M1.5M
20191.5M1.5M1.5M1.5M
20182.2M2.3M2.3M1.5M
20171.2M1.2M1.2M2.1M
2016775.3K923.5K1.1M1.2M
2015000627.0K

Tracking the Latest Insider Buys and Sells of Syndax Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
goldan keith a.
bought
25,037
20.0298
1,250
chief financial officer
Feb 07, 2024
meury william
acquired
-
-
17,000
-
Feb 07, 2024
goldan keith a.
acquired
-
-
46,700
chief financial officer
Feb 07, 2024
morrison briggs
acquired
-
-
17,000
-
Feb 07, 2024
huber martin h. jr.
acquired
-
-
17,000
-
Feb 07, 2024
podlesak dennis
acquired
-
-
34,000
-
Feb 07, 2024
jarrett jennifer
acquired
-
-
17,000
-
Feb 07, 2024
metzger michael a
acquired
-
-
146,250
chief executive officer
Feb 07, 2024
katkin keith
acquired
-
-
17,000
-
Feb 07, 2024
gallagher neil
acquired
-
-
47,813
president, head of r&d

1–10 of 50

Which funds bought or sold SNDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
39,000
636,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
21,900
238,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
102
214,844
388,844
0.05%
May 20, 2024
Virtu Financial LLC
sold off
-100
-258,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
added
6.04
388,270
2,701,970
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
1.53
192,512
1,822,060
-%
May 16, 2024
COMERICA BANK
reduced
-3.55
1,327
22,634
-%
May 15, 2024
Ghost Tree Capital, LLC
new
-
3,570,000
3,570,000
0.99%
May 15, 2024
Zimmer Partners, LP
reduced
-43.66
-2,255,910
3,689,000
0.08%
May 15, 2024
ORBIMED ADVISORS LLC
unchanged
-
3,830,310
41,626,200
0.76%

1–10 of 45

Are Funds Buying or Selling SNDX?

Are funds buying SNDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SNDX
No. of Funds

Unveiling Syndax Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
kynam capital management, lp
6.67%
5,660,000
SC 13G
Feb 14, 2024
point72 asset management, l.p.
3.3%
2,834,499
SC 13G/A
Feb 13, 2024
avidity partners management lp
4.7%
3,950,000
SC 13G/A
Feb 13, 2024
vanguard group inc
5.11%
4,335,353
SC 13G
Feb 08, 2024
wellington management group llp
8.94%
7,585,221
SC 13G/A
Jan 25, 2024
state street corp
5.91%
5,016,224
SC 13G/A
Jan 25, 2024
blackrock inc.
8.3%
7,015,548
SC 13G/A
Oct 31, 2023
point72 asset management, l.p.
4.5%
3,156,982
SC 13G
Oct 05, 2023
frazier life sciences public fund, l.p.
0.0%
0
SC 13G/A
Feb 14, 2023
nantahala capital management, llc
1.4%
975,705
SC 13G/A

Recent SEC filings of Syndax Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
3
Insider Trading
May 15, 2024
8-K
Current Report
May 08, 2024
8-K
Current Report
May 08, 2024
10-Q
Quarterly Report
Apr 02, 2024
DEFA14A
DEFA14A
Apr 02, 2024
DEF 14A
DEF 14A
Apr 02, 2024
ARS
ARS
Mar 18, 2024
8-K
Current Report

Peers (Alternatives to Syndax Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Syndax Pharmaceuticals Inc News

Latest updates
Defense World6 hours ago

Syndax Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q4
Revenue922.8%126,57612,3753793793803793793793803793793793803793793791,193305305305305
Operating Expenses-4.9%30,82732,40722,71327,54220,24020,23216,98915,47914,58513,52815,75315,19019,71318,22019,330------
  S&GA Expenses1.8%6,9276,8015,8425,6724,7185,8246,0465,9175,0833,6053,4633,9113,8924,1254,479------
  R&D Expenses-6.7%23,90125,60616,87121,87015,52214,40810,9439,5629,5029,92312,29011,27915,82114,09514,851------
Interest Expenses-101.1%-7.00649634623635635638449-------------
Net Income566.1%96,198-20,639-22,910-27,723-20,423-20,437-17,062-15,236-14,000-12,829-14,916-14,302-18,837-17,338-18,388------
Net Income Margin102.6%0.18*-6.79*-60.31*------------------
Free Cashflow503.5%100,695-24,958-24,059------------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-11.4%54361339943146049736040642245024026328030117919310564.0076.0087.0099.00
  Current Assets-21.9%45458138140944249035839242044823826327929917719210462.0075.0086.0098.00
    Cash Equivalents-61.2%11529595.0097.0058.0074.0071.0012018922271.0068.0064.0011556.0054.0045.0025.0031.0027.0058.00
  Net PPE-37.5%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-12.9%51.0059.0040.0031.0024.0030.0022.0044.0048.0041.0040.0048.0051.0048.0047.0045.0052.0032.0032.0032.0031.00
  Current Liabilities-12.5%51.0058.0039.0030.0024.0029.0021.0031.0031.0021.0029.0024.0025.0019.0015.0012.0019.0018.0018.0017.0016.00
Shareholder's Equity-11.2%49255435940043646733836237540819921522825213214854.0032.0044.0055.0069.00
  Retained Earnings-8.0%-974-902-829-778-734-693-653-618-580-543-639-619-596-568-548-527-510-495-481-468-453
  Additional Paid-In Capital0.8%1,4671,4561,1901,1791,1701,161994982956952839834825821680675564527525524522
Shares Outstanding0.2%85.0085.0070.0069.0069.0068.0060.0060.0059.0052.0052.0052.00---------
Float----1,452,442---1,084---833---500---208-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-102.1%-83,548-41,349-44,653-35,371-39,228-22,894-28,544-40,306-41,931100,709-24,944-24,045-22,589-15,631-18,297-21,407-15,925-12,727-8,529-12,525-16,831
  Share Based Compensation6.9%8,8998,3278,3218,0656,2384,2414,3623,9383,4783,9293,3813,2402,7672,0353,0632,1301,8291,5251,5501,3381,592
Cashflow From Investing-510.2%-99,399-16,29040,07773,90719,915-137,629-6,793-49,9488,182-59,95626,63121,680-29,228-64,14019,275-78,612-19,0536,59612,364-18,93112,752
Cashflow From Financing-99.2%2,168258,4831,8511,3242,474163,502-13,52521,720557109,7791,7056,020960138,6581,767109,00154,99858.0080.006.0028,426
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SNDX Income Statement

2024-03-31
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 56,492$ 34,054
Selling, general and administrative23,02211,961
Total operating expenses79,51446,015
Loss from operations(79,514)(46,015)
Other income (expense), net:  
Interest expense(55)(40)
Interest income7,2565,076
Other expense(87)(147)
Total other income, net7,1144,889
Net loss(72,400)(41,126)
Other comprehensive loss:  
Unrealized (loss) gain on short-term investments(974)470
Comprehensive loss(73,374)(40,656)
Net loss attributable to common stockholders$ (72,400)$ (41,126)
Net loss per share attributable to common stockholders—basic$ (0.85)$ (0.59)
Net loss per share attributable to common stockholders—diluted$ (0.85)$ (0.59)
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders —basic85,213,20069,438,890
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted85,213,20069,438,890

SNDX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 114,615$ 295,394
Short-term investments319,963275,304
Short-term deposits8,5836,885
Other receivable6,0730
Prepaid expenses and other current assets4,6653,293
Total current assets453,899580,876
Long-term investments87,41629,829
Property and equipment, net58
Right-of-use asset, net1,2431,487
Restricted cash217217
Other assets248463
Total assets543,028612,880
Current liabilities:  
Accounts payable8,8099,961
Collaboration payable, net7,5477,232
Accrued expenses and other current liabilities33,39539,856
Current portion of right-of-use liability1,0421,035
Current portion of capital lease1212
Total current liabilities50,80558,096
Long-term liabilities:  
Right-of-use liability, less current portion327578
Capital lease, less current portion710
Total long-term liabilities334588
Total liabilities51,13958,684
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value, 200,000,000 shares authorized; 84,979,686 and 84,826,632 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively88
Additional paid-in capital1,467,4371,456,370
Accumulated other comprehensive (loss) gain(756)218
Accumulated deficit(974,800)(902,400)
Total stockholders’ equity491,889554,196
Total liabilities and stockholders’ equity$ 543,028$ 612,880
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEsyndax.com
 INDUSTRYBiotechnology
 EMPLOYEES107

Syndax Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Syndax Pharmaceuticals Inc? What does SNDX stand for in stocks?

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syndax Pharmaceuticals Inc (SNDX)?

As of Fri Jun 21 2024, market cap of Syndax Pharmaceuticals Inc is 1.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers. The fair value of Syndax Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syndax Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syndax Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

What is Syndax Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, SNDX's PE ratio (Price to Earnings) is -7.08 and Price to Sales (PS) ratio is 13.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.